Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

1093 - Retrospective audit to assess impact of tumour biology on locoregional treatment outcome in breast cancer


20 Dec 2015


Poster presentation 2


Pooja Padmanaban


Annals of Oncology (2015) 26 (suppl_9): 16-33. 10.1093/annonc/mdv519


P. Padmanaban1, V. Parmar1, N. Nair1, R.A. Badwe1, N. Hariharan1, R. Hawaldar2, V. Vanmali2, A. Bansode2, S. Siddique2

Author affiliations

  • 1 Breast Services, Surgical Oncology, Tata Memorial Hospital Centre, 400012 - Mumbai/IN
  • 2 Institutional Review Board, Tata Memorial Hospital Centre, 400012 - Mumbai/IN


Abstract 1093


Extent of surgery in breast cancer is based on breast-tumor ratio and radiological features and not on biological tumour subtype. We wish to assess association of tumour biology and locoregional treatment.


A retrospective audit of 2240 women with unilateral stage I-III breast cancer treated at a single institution during 2009-2011. Based on IHC, 3 subtypes were identified namely, Hormone receptor positive (ER &/or PgR +ve & Her2neu negative), Her 2 neu positive (Her 2 neu score 3 + , or 2+ & FISH amplified, with any ER/PR), and Triple negative/TNBC(ER/PgR & Her 2 neu negative). Tumors reported Her 2 neu equivocal without confirmatory FISH result were excluded. Locoregional-recurrence free survival (LRFS) was plotted using Kaplan Meier graphs. Cox regression models were used to assess interaction with known prognostic factors. Objectives were to assess LRFS within subtypes depending on extent of locoregional treatment.


Median age was 48 yrs (range 18-84), 1613(66.1%) were operable breast cancers, 627(33.9%) were locally advanced; median cT was 4.3cm (range 1.5-18), 1047(46.7%) were HR + , 491(21.9%) Her 2 neu + and 702(31.3%) were TNBC. NACT was administered in 1413(63.1%), 827(36.9%) were operated upfront. 1208(53.9%) underwent BCT, 1032(46.1%) underwent MRM. At median follow up of 45mth, LRFS was significantly better for HR+ than TNBC and Her 2 neu+ for both BCT(p = 0.0001) and MRM(p = 0.005). However, no significant difference in LRFS was seen within each subtype with respect to extent of surgery (HR+ p = 0.125, TNBC p = 0.430, HER2neu+ p = 0.444). By Cox regression, younger age (HR 1.026 95%CI 1.009–1.043, p = 0.003), nodal positivity (HR 2.316, 95%CI 1.578–3.399, p = 0.0005) and advanced stage (HR 1.669, 95%CI 1.079–2.581, p = 0.021) were associated with worse LRFS. HR+ had best LRFS, followed by TNBC (HR 3.316, 95%CI 1.783–6.164, p = 0.0005), and Her 2 neu+ (HR 4.169, 95%CI 2.180–7.974, p = 0.0005). Extent of surgery had no impact on LRFS within each subtypes.


LRFS was dictated by disease biology rather than extent of local surgery. Within each subtype, type of surgery did not impact LRFS. Younger age, nodal positivity and advanced stage were associated with worse LRFS.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings